secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0000950170-22-001684
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences: KSI-301 fails primary endpoint in wet AMD Phase 2b/3 trial
---------------------------------------------------------------------------

- Primary endpoint not met: KSI-301 failed to show non-inferior visual acuity gains vs aflibercept in wet AMD.
- Cash and cash equivalents at Dec 31, 2021 were approximately $731.5M.
- Pre-specified secondary analysis: 59% of KSI-301 patients achieved 5-month dosing with comparable visual acuity and anatomic improvements.
- Safety: KSI-301 generally safe; intraocular inflammation in 3.2% vs 0% for aflibercept; all resolved.
- Trial randomized 559 participants, ~80% in US; flexible long-interval regimen for KSI-301 vs fixed 2-month for aflibercept.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022001684/0000950170-22-001684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022001684/kod-20220223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-001684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer